Aerie Pharmaceuticals has completed enrollment in a phase 2b clinical trial investigating AR-15512 ophthalmic solution for dry eye disease, according to a press release.
The randomized, double-masked, vehicle-controlled COMET-1 trial is evaluating the safety and efficacy of AR-15512 (TRPM8 agonist) in 369 patients who were randomly assigned to receive AR-15512 0.0014%, AR-15512 0.003% or AR-15512 vehicle.
“When activated, the TRPM8 receptor may increase tear production, a sign for dry eye disease, and its cooling sensation may lead to reduction in discomfort and ocular pain, a symptom of